Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2021

Ocuphire Pharma Presenting at Four Conferences in September

Sep 2, 2021

Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update

Aug 12, 2021

Ocuphire Pharma Presenting at Two Conferences in August

Aug 6, 2021

Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Jul 22, 2021

Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July

Jul 13, 2021

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 9, 2021

Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

Jun 30, 2021

Processa Pharmaceuticals Enters Into A Licensing Agreement With Ocuphire Pharma, Inc., For The Development Of RX-3117

Jun 17, 2021

Ocuphire Announces Addition to the Russell Microcap® Index

Jun 11, 2021